

UC San Diego

UC San Diego Previously Published Works

Title

Posttranscriptional control of the stem cell and neurogenic programs by the nonsense-mediated RNA decay pathway.

Permalink

<https://escholarship.org/uc/item/93z3f9zz>

Journal

Cell Reports, 6(4)

Authors

Lou, Chih

Shao, Ada

Shum, Eleen

et al.

Publication Date

2014-02-27

DOI

10.1016/j.celrep.2014.01.028

Peer reviewed

Published in final edited form as:

Cell Rep. 2014 February 27; 6(4): 748–764. doi:10.1016/j.celrep.2014.01.028.

Posttranscriptional Control of the Stem Cell and Neurogenic Programs by the Nonsense-Mediated RNA Decay Pathway

Chih H. Lou¹, Ada Shao¹, Eleen Y. Shum¹, Josh L. Espinoza¹, Lulu Huang^{1,2}, Rachid Karam¹, and Miles F. Wilkinson^{1,3,*}

¹Department of Reproductive Medicine, School of Medicine, University of California, San Diego, La Jolla, CA 92093-0695, USA

³Institute of Genomic Medicine, University of California, San Diego, La Jolla, CA 92093-0695, USA

SUMMARY

The mechanisms dictating whether a cell proliferates or differentiates have undergone intense scrutiny but remain poorly understood. Here, we report that a central component in the nonsense-mediated RNA decay (NMD) pathway—UPF1—plays a key role in this decision by promoting the proliferative, undifferentiated cell state. UPF1 acts, in part, by destabilizing the NMD substrate encoding the TGF β inhibitor, SMAD7, and stimulating TGF β signaling. UPF1 also promotes the decay of mRNAs encoding many other proteins that oppose the proliferative, undifferentiated cell state. Neural differentiation is triggered when NMD is downregulated by neurally expressed microRNAs (miRNAs). This UPF1-miRNA circuitry is highly conserved and harbors negative feedback loops that act as a molecular switch. Our results suggest that the NMD RNA decay pathway collaborates with the TGF- β signaling pathway to lock-in the stem-like state, a cellular state that is stably reversed when neural differentiation signals that induce NMD-repressive miRNAs are received.

INTRODUCTION

The underlying mechanisms dictating whether a cell proliferates or differentiates has been one of the most important questions in the field of biology for the past several decades. In contrast to the plethora of knowledge about transcriptional mechanisms that control such proliferation vs. differentiation decisions, very little is known about the role of post-transcriptional mechanisms in this process. Recent studies have identified specific RNA-binding proteins and microRNAs (miRNAs) that can swing the balance in one direction or another, but the mechanisms underlying these pathways remains poorly understood (Melton and Blelloch, 2010).

In this communication, we report that the nonsense-mediated mRNA decay (NMD) pathway plays a crucial role in this decision. NMD is a conserved RNA degradation mechanism that depends on several proteins, including UPF1, an RNA helicase with ATPase activity that is absolutely essential for NMD, and the adapter proteins, UPF2 and UPF3B, that are required

© 2014 The Authors. Published by Elsevier Inc. All rights reserved.

*Correspondence: mfwilkinson@ucsd.edu.

²Present address: Isis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, CA 92010, USA

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

for specific branches of NMD (Popp and Maquat, 2013; Schweingruber et al., 2013). NMD was originally identified as a quality control pathway that rapidly degrades aberrant transcripts harboring premature stop (nonsense) codons (PTCs) (Chang et al., 2007). Recent studies have shown that NMD is not only a quality control pathway, but also a regulatory pathway that controls normal gene expression. Gene expression profiling studies have shown that either loss or depletion of NMD factors in species scaling the phylogenetic scale leads to the dysregulation of ~3%–15% of normal transcripts (Schweingruber et al., 2013). While many of these dysregulated mRNAs are probably indirectly regulated by NMD, studies have begun to identify some of them as direct NMD targets (Hurt et al., 2013; Kim et al., 2012; Tani et al., 2013). One of the “NMD-inducing features” in these direct NMD substrates is the presence one or more introns downstream of the stop codon that defines the end of the open reading frame (ORF) encoding the protein (Chang et al., 2007). Intron splicing leads to deposition of a set of proteins called the exon-junction complex (EJC), which interact with UPF1 and other NMD factors recruited at the site of translation termination, ultimately leading to rapid mRNA decay. Evidence suggests that mRNAs harboring a stop codon in the final exon avoid rapid mRNA decay because actively translating ribosomes strip off EJCs before encountering the stop codon during the pioneer round of translation (Dostie and Dreyfuss, 2002; Chang 2007). Other NMD-inducing features are upstream ORFs (uORFs) and long 3' UTRs, which trigger NMD by mechanisms that are not clearly understood (Schweingruber et al., 2013).

The finding that NMD regulates the levels of many normal mRNAs raises the possibility that NMD regulates normal biological events. In support of this possibility, studies conducted in a wide range of organisms have shown that loss or depletion of NMD factors causes specific developmental defects (Vicente-Crespo and Palacios, 2010). While these studies have clearly shown that NMD factors have roles in various biological processes, it has not been determined whether this is because of NMD's ability to regulate normal gene expression programs (i.e., through decay of subsets of normal mRNAs) or its quality control function (i.e., through decay of aberrant transcripts).

The notion that NMD's ability to regulate normal gene expression programs is physiologically important is supported by the growing evidence that NMD itself is subject to regulation (Huang and Wilkinson, 2012; Karam et al., 2012). Our laboratory recently reported that the neurally expressed miRNAs miR-128-1 and -2 repress NMD through direct silencing of UPF1 and the EJC core protein MLN51 (Bruno et al., 2011). While we did not address the physiological relevance of this regulation, we obtained several lines of evidence suggesting that these two miRNAs (which are identical and thus we will henceforth collectively refer to as “miR-128”) are important for nervous system development. In the present paper, we directly address the roles of miR-128 and one of its targets, UPF1, as well as their regulatory relationship, in controlling the decision to maintain the undifferentiated cell state or undergo neural differentiation.

Results

UPF1 Promotes the Stem-Like State and is Downregulated to Permit Neural Differentiation

Given that UPF1 is a core NMD factor that we previously showed is a direct target of a neural-promoting miRNA (Bruno et al., 2011), we examined whether UPF1 levels are regulated in the nervous system. We found that *Upf1* mRNA levels decrease during mouse embryonic brain cortex development and when mouse neural stem cells (mNSCs) and human neural progenitor cells are induced to undergo maturation (Figures 1A and S1A). *Upf1* mRNA is also downregulated in differentiated P19 cells (Figure S1A), which undergoes neural differentiation in response to retinoic acid (RA) treatment. To assess the generality of this downregulatory response, we examined other NMD factors and found that

Upf2, *Upf3b*, *Smg1*, and *Smg6* mRNA were also downregulated in mNSCs undergoing maturation (Figure 1A). In contrast, *Smg5* and *Smg7* mRNA levels were modestly upregulated in maturing mNSCs.

The downregulation of UPF1 and most other NMD factors that we tested raised the possibility that the magnitude of NMD itself is reduced during neural differentiation and maturation. In support of this, three well-established NMD substrates—*Atf3*, *Gadd45b*, and *Gas5* mRNA (Chan et al., 2007; Huang et al., 2012)—were upregulated in differentiating P19 cells (Figure S1B). To directly assess NMD activity, we used a dual NMD reporter system (Boelz et al., 2006) and found that the ratio of PTC⁻/PTC⁺ transcripts decreased when P19 cells underwent neural differentiation, indicative of decreased NMD activity (Figures 1B and S1C). NMD activity was also decreased during mNSCs maturation, as assessed using a tetracycline (tet)-promoter-based NMD reporter system to directly measure mRNA half-life (Singh et al., 2008) (Figure 1C).

To determine whether this NMD downregulatory response has a causal role in neural differentiation, we maintained UPF1 levels in differentiating P19 cells by expressing modest levels of exogenous UPF1 from a heterologous promoter. We found that this blocked the upregulation of neural differentiation markers and largely prevented the downregulation of stem-cell markers (Figures 1D–1F). As further evidence that UPF1 promotes the stem-like state, we found that UPF1 overexpression was sufficient to upregulate stem-cell markers (Figure S1D). To determine whether repression of UPF1 is sufficient to elicit neural differentiation, we used RNA interference (RNAi) to deplete UPF1 in P19 cells. We found that UPF1 knockdown was sufficient to elicit the initial stages of differentiation, as assessed by the upregulation of neural differentiation markers and the downregulation of stem-cell markers (Figures 1G and S1E). UPF1 knockdown also stimulated neural maturation, as assessed in mNSCs grown under pro-neural differentiation conditions (Figure 1H).

Since UPF1 is an essential factor for another RNA decay pathway—SMD (Gong et al. 2009)—this raised the possibility that the UPF1 downregulatory response promotes neural maturation because it depresses the SMD pathway. This is unlikely to be case, as we found that depleting the essential SMD factor, STAU1, did not promote mNSC maturation, as assessed by early neural maturation markers (Figure S1F). To assess whether the ability to repress neural maturation is a general property of NMD or mediated by UPF1 in particular, we examined the effect of loss of the NMD factor, UPF3B, which, like UPF1, is downregulated during neural maturation (Figure 1A). We isolated mNSCs from the *Upf3b*-null mice we recently generated (Huang et al., 2012) and found that when grown under differentiating conditions, these *Upf3b*-null mNSCs had significantly higher level of early neural markers than littermate control mNSCs, suggesting that UPF3B normally suppresses the ability of these cells to differentiate (Figure S1G). Taken together, these data indicate that the NMD downregulatory response that occurs during the neural differentiation program is essential for the normal differentiation and maturation of neural cells.

UPF1 Promotes Proliferation at the G1/S Transition

Our finding that UPF1 represses neural differentiation and maturation raised the possibility that it does so because UPF1 favors the proliferative state. Indeed, we found that depleting UPF1 in undifferentiated P19 cells reduced their ability to proliferate (Figure 1I). Conversely, modest overexpression of UPF1 was sufficient to increase their proliferation (Figure 1J). Because UPF1 is normally downregulated during neural differentiation (Figures 1A and S1A), this led us to next ask whether this downregulatory response is necessary for P19 cells to cease proliferating in response to a differentiation signal. Indeed, we found that maintenance of UPF1 levels with an *Upf1* expression vector prevented the cessation of

proliferation that normally occurs when P19 cells are induced to undergo neural differentiation by RA treatment (Figure 1K).

It is well established that neural differentiation leads to inhibited cell proliferation at the G1/S transition point of the cell cycle (Orford and Scadden, 2008). Thus, if the UPF1 downregulatory response we uncovered has a role in this cell cycle blockade, UPF1 knockdown ought to inhibit progression through G1/S. Indeed, we found that depletion of UPF1 caused an accumulation of cells in G1 and reduced number of cells in S phase, indicative of a G1/S transition block (Figures 1L and S1H). As a positive control, we tested the standard neural differentiation signal, RA, and found it had the same effect (Figures 1L and S1H). Forced UPF1 expression in RA-treated P19 cells largely reversed the G1/S blockade, providing direct evidence that UPF1 drives cells to progress through this transition point of the cell cycle (Figure 1L).

NMD Selectively Degrades mRNAs Encoding Proliferation Inhibitory Factors

Our finding that the NMD factor, UPF1, promotes progression through G1/S raised the possibility that NMD promotes the decay of mRNAs encoding inhibitory proteins that block progression through this stage of the cell cycle. Ten factors with well-defined G1/S inhibitory activity are known, most of which are repressed in stem cells to maintain a high rate of self-renewal activity and must be activated for such cells to leave the mitotic cycle and undergo terminal differentiation (Orford and Scadden, 2008). As a first step towards evaluating whether the mRNAs encoding any of these G1/S inhibitors are NMD targets, we examined whether they have known NMD-inducing features, such as an uORF, a long 3' UTR (>1 kb), an intron in the 3' UTR, or were alternatively spliced to generate one or more of these features (see Introduction). We found that 8 of these 10 mRNAs had NMD-inducing features (Table S1). To empirically determine whether any of these 8 mRNAs are regulated by NMD, we examined whether they are upregulated when NMD is perturbed. Quantitative (q) RT-PCR analysis demonstrated that transcripts from 4 of these genes—*p21 (Cdkn1a)*, *p27 (Cdkn1b)*, *p57 (Cdkn1c)*, and *Mapk6 (Erk3)*—were significantly upregulated in UPF1-depleted P19 cells (Figure 2A). Since destabilization is the hallmark of direct NMD target mRNAs (Chang et al., 2007), we performed RNA half-life analysis on these 4 mRNAs and found they were stabilized in response to UPF1 depletion (Figures 2B and S2A). Together with their increased steady-state level in response to NMD perturbation and the fact they have NMD-inducing features, this provided strong evidence that these 4 transcripts are direct NMD targets. Further support that *p21* mRNA is a direct NMD target is that it is stabilized when its putative NMD-inducing feature—an uORF—is deleted (Kim et al., 2012).

If UPF1 stimulates transition through the G1/S phase of the cell cycle by selectively promoting the decay of mRNAs encoding G1/S proliferation inhibitory factors, this predicts it would tend to *not* target mRNAs encoding G1/S proliferation *activator* factors. To test this, we analyzed the mRNAs encoding the eight proteins with well-established roles as direct activators of G1/S progression (Orford and Scadden, 2008) (Table S1) and found that none of them were significantly upregulated in response to depletion of UPF1 (Figure 2A). Instead, the mRNAs encoding five of these factors—CCND1, CCNE, CDC25A, CDK4, and MYC—were significantly downregulated when UPF1 was depleted (Figure 2A), consistent with our finding that UPF1 downregulation triggers reduced cell proliferation (Figures 1I and S1H). We conclude that NMD selectively targets mRNAs encoding G1/S inhibitor proteins, thereby providing a possible mechanism by which UPF1 promotes proliferation.

NMD Selectively Degrades mRNAs Encoding Neural Differentiation Factors

We postulated that an additional mechanism by which NMD promotes the undifferentiated cell state is by degrading mRNAs encoding differentiation factors. We focused our analysis on neural differentiation factors since deficiencies in NMD cause intellectual disability (Tarpey et al., 2007). Only well-established neural differentiation factors were selected, including those acting in neural signaling pathways, transcription factors that reprogram cells into neurons, and downstream effectors that have been shown to have essential roles in neural differentiation and/or specification (Table S2). We found that of the 29 neural differentiation factors that fulfill these criteria, 23 are encoded by mRNAs harboring known NMD-inducing features (Table S2), 19 of which were significantly upregulated in response to UPF1 depletion in P19 cells (Figure 2A). At least 16 of these 19 were stabilized by NMD depletion, based on mRNA half-life analysis in P19 cells (Figures 2B and S2A), but note that this is a conservative estimate, as this assay does not always detect direct NMD targets (Chan et al., 2007). To test whether this was a selective property, we next examined whether mRNAs encoding *anti*-neural differentiation factors were also targeted by NMD. We found that 4 of 18 factors with well-defined roles in repressing neural differentiation and/or maturation had an NMD-inducing feature and were significantly upregulated in UPF1-depleted cells (Figure 2A and Table S3). We examined the half-life of two of these mRNAs, *Lefty1* and *Smad1*, and found that neither was stabilized upon UPF1 depletion, suggesting they are not direct NMD targets (Figure S2B). Taken together, these results provide evidence that NMD preferentially degrades transcripts encoding neural differentiation factors. This raised the possibility that NMD promotes the undifferentiated cell state through this property, a possibility we explore below.

NMD Represses Neural Differentiation by Targeting the TGF- β Signaling Pathway

A well-established mechanism that promotes neural differentiation is repression of the TGF- β /BMP signaling pathway (Seuntjens et al., 2009). This was of interest in light of our finding that several of the mRNAs targeted for decay by UPF1 in P19 cells encode TGF- β /BMP signaling inhibitors: SMURF1, SMURF2, SMAD6, and SMAD7 (Figures 2 and S2A). These mRNAs were also upregulated in response to UPF1 knockdown in mNSCs (Figure 3A). mNSCs lacking another NMD factor, UPF3B, also upregulated *Smad6* and *Smad7* mRNA, as well as other mRNAs (Figure S3A), providing strong evidence these are direct NMD targets. Since UPF1 targets these mRNAs for decay and they encode negative regulators of TGF- β /BMP signaling, this raised the possibility that UPF1 promotes TGF- β signaling pathway. In support of this hypothesis, we found that UPF1 depletion inhibited TGF- β signaling, as shown by the decreased expression of *Smad2* and the TGF- β signaling target genes *Cdx4* and *Lhx1* (Liu et al., 2011) (Figure 3B). UPF1 depletion also decreased the level of phosphorylated SMAD2 (Figure 3C), a hallmark of TGF- β signaling (Massague and Xi, 2012). To further test the hypothesis that UPF1 promotes TGF- β signaling, we prevented the downregulation of UPF1 expression that normally occurs during neural differentiation by expressing modest levels of UPF1 from an expression vector and found that this reduced the decrease in phospho-SMAD2 levels that normally accompanies neural differentiation (Figure S3B). Together, these data indicated that UPF1 promotes TGF- β signaling, thereby providing a potential molecular pathway by which UPF1 controls neural differentiation.

Since the mRNA encoding the TGF- β inhibitor, SMAD7, was the most strongly upregulated mRNA in response to UPF1 knockdown (Figure 2A), we deemed it a good candidate to act in a NMD-based circuit to control neural differentiation. In this proposed circuit, *Smad7* mRNA is stabilized by NMD downregulation, which leads to increased SMAD7 protein level and, as a consequence, repressed TGF- β signaling, leading to neural differentiation (Figure 3D). The existence of this NMD-*Smad7* circuit was supported by the following:

First, depletion of UPF1 increased the level of SMAD7 protein in P19 cells (Figure 3C). Second, depletion of SMAD7 in P19 cells inhibited their ability to undergo neural differentiation (Figure 3E), consistent with past studies that have shown that SMAD7 promotes neural differentiation (Ozair et al., 2013). Third, several lines of evidence indicated that *Smad7* mRNA is directly targeted for decay by NMD: (i) *Smad7* mRNA was upregulated in response to UPF1 depletion in both P19 (Figure 2A) and mNSC cells (Figure 3A), (ii) *Smad7* mRNA was strongly stabilized by UPF1 knockdown in P19 cells (Figure 2B), (iii) *Smad7* mRNA was upregulated in response to loss of the NMD factor UPF3B (Figure S3A), and (iv) *Smad7* possesses three putative features that are capable of eliciting NMD: an uORF in the 5' UTR, a long 3' UTR, and an intron in the 3' UTR (see Introduction and Table S2). To assess their role, we made use of a tetracycline (tet)-regulated vector system that allows one to identify destabilizing *cis* elements by virtue of their ability to destabilize the normally stable β -globin mRNA (Singh et al., 2008). We independently subcloned the *Smad7* 5' UTR and 3' UTR upstream and downstream, respectively, of the β -globin coding region in this vector and found that both greatly destabilized β -globin mRNA, an effect that was partially reversed when *Upf1* levels were depleted (Figures 3F and 3G). This verified that *Smad7* mRNA is an NMD target and it indicated that it is downregulated by NMD by virtue of features in both its 5' and 3' UTR.

We performed a rescue experiment to directly address whether *Smad7* acts in a functional circuit downstream of NMD. Using a modest dose of *Smad7* shRNA, we largely prevented the upregulation of SMAD7 that normally occurs in response to NMD repression during neural differentiation (Figure 3H). We found that this partially rescued TGF- β signaling, as measured with the downstream effectors *Cdx4* and *Lhx1* (Figure 3H), and largely prevented neural differentiation, as measured with the neural markers *Nestin* and *Tubb3* (Figure 3I). We also tested whether overexpression of UPF1 had the reciprocal affect, but observed no change in *Smad7* mRNA levels (Figure S3C), implying that UPF1 is not rate limiting for NMD in P19 cells. Since there is evidence that SMAD7 not only promotes neural differentiation but also inhibits cell proliferation (Briones-Orta et al., 2011), we also assessed whether SMAD7 has a role in NMD's pro-proliferation function. We found that knockdown of SMAD7 did not significantly rescue the effect of NMD on cellular proliferation in P19 cells (Figures S3D, S3E, and S3F), suggesting that NMD regulates proliferation independently of SMAD7. We conclude that SMAD7 participates with NMD in a circuit that specifically acts on neural differentiation, not cellular proliferation (Figure 3D).

Given that UPF1 promotes TGF- β signaling, this raised the possibility that UPF1 might stimulate mesoderm differentiation, which is stimulated by TGF- β signaling (Nakaya et al., 2008). Indeed, we found that UPF1 knockdown reduced the ability of P19 cells to differentiate down the mesoderm lineage (in response to Activin), as assessed using the mesodermal markers Brachury (T) and Goosecoid (Gsc) (Nakaya et al., 2008) (Figure 3J). This repression of mesodermal differentiation was reversed by preventing the upregulation of SMAD7 that normally occurs in response to UPF1 depletion (using low-dose *Smad7* shRNA; Figure 3J). Together, these data support the notion that UPF1/SMAD7 circuit acts through TGF- β signaling as a binary switch to control whether precursor cells differentiate down the neural vs. mesoderm cell lineage (Figure 3D).

A NMD-miRNA Circuit that Influences Cell Fate

We previously reported that UPF1 is a direct target of miR-128, a brain-enriched miRNA expressed in neurons in the cortex and hippocampus *in vivo* whose expression is dramatically upregulated during neural differentiation and maturation *in vitro* (Smirnova et al., 2005; Bak et al., 2008; Bruno et al., 2011). Coupled with the results described above,

this raised the possibility that miR-128 serves to repress UPF1 expression in order to drive neural precursor cells to undergo differentiation and maturation (Figure 4A). Consistent with this possibility, miR-128 and *Upf1* RNA levels are inversely expressed during neuron maturation and differentiation *in vitro* and during brain development *in vivo* (Figures 1A and S1A) (Bruno et al., 2011). To directly test this hypothesis, we first performed a rescue experiment in which we asked whether preventing the *Upf1* downregulatory response that normally occurs when miR-128 is induced is sufficient to block neural differentiation. Indeed, we found that when *Upf1* levels were maintained at pre-treatment levels with an *Upf1* expression vector, that this largely inhibited miR-128-induced neural differentiation of P19 cells (Figure S4A). Since miR-128 promotes neural differentiation, this predicts it would also inhibit proliferation. Gain-of-function evidence for this was the finding that ectopic expression of miR-128 inhibited cellular proliferation and inhibited cell cycle progression through G1/S (Figures S4B and C). For a loss-of-function approach, we engineered a miR-128 decoy to inhibit miR-128 function (Figure S4D). This miR-128 decoy, which inhibited P19 cells from undergoing neural differentiation in response to RA (Figure S4E), also inhibited the blockade in cell proliferation that normally accompanies neural differentiation (Figure S4F). These rescue experiments showed that rescuing *Upf1* expression in miR-128 mimic-treated cells reversed the cell proliferation block in the G1/S transition (Figures S4C and S4G). Taken together, these data indicated that (i) miR-128 promotes neural differentiation; (ii) miR-128 inhibits cellular proliferation at the G1/S transition, (iii) miR-128 acts, at least in part, through UPF1 to mediate these actions (Figure 4A).

A Self-Reinforcing NMD-miRNA Feedback Control Circuit

Our finding that UPF1 downregulation promotes neural differentiation and maturation (Figures 1G and 1H), raised the possibility that this UPF1 downregulatory response is a necessary prerequisite for the dramatic induction of miR-128 expression that occurs during neural differentiation and maturation (Bruno et al., 2011). In other words, we hypothesized that not only does miR-128 negatively regulate UPF1, but UPF1 negatively regulates miR-128 (Figure 4A). In support, we found that depletion of UPF1 was sufficient to strongly induce miR-128 in P19 cells (Figure 4B). This induction was largely prevented by the TGF- β signaling inducer Activin (Figure 4B), suggesting that miR-128 is induced as a result of repression of TGF- β signaling. This was further supported by the finding that incubation with the TGF- β inhibitor, TGF-I (SB431542) (Halder et al., 2005), was sufficient to strongly induce miR-128 expression (Figure 4B). This data suggest the existence of a self-reinforcing negative-feedback circuit (Figure 4A and see Discussion).

We screened other neurally expressed miRNAs to determine whether they also target NMD factors. Figure S4I shows that several neurally expressed miRNAs are predicted to target NMD factors, based on using the miRNA target prediction programs MicroCosm, TargetScan and miRanda-mirSVR. We empirically tested the four miRNAs predicted to target the NMD gene, *UPF3B* (Figure S4I), since mutations in this gene cause intellectual disability (Tarpey et al., 2007). We found that three of four of these miRNAs—miR-9, -124, and -128—repressed luciferase expression from a reporter harboring the *UPF3B* 3' UTR (Figures 4C and 4D). We tested miR-9 further because of the abundant evidence it promotes neural differentiation (Sun et al., 2013) and found that the miR-9 mimic also downregulated endogenous *UPF3B* mRNA level and a sequence-specific miR-9 inhibitor upregulated endogenous UPF3B protein (Figure 4E).

Given that miR-128 expression is repressed by NMD (Figure 4F), we asked whether miR-9 and miR-124 are regulated in this manner as well. In support, we found that depletion of UPF1 upregulated the expression of not only miR-128, but also miR-9 and miR-124 (Figure

4G). To distinguish between these miRNAs being regulated by UPF1 specifically or by NMD in general, we examined the effect of loss of another NMD factor: UPF3B. MiR-9 and -128 were upregulated in *Upf3b*-null mNSCs (Figure 4G), which together with their induction in response to depletion of UPF1 strongly suggests they are negatively regulated by the NMD pathway. In contrast, miR-124 was not upregulated in *Upf3b*-null mNSCs, suggesting that miR-124 is either specifically regulated by UPF1 or it is regulated by an *Upf3b*-independent branch of the NMD pathway (Chan et al., 2007; Huang et al., 2011). Together, these results support a model in which miR-128 and other neurally expressed miRNAs participate in an NMD-driven regulatory circuit that dictates whether a neural precursor cell remains in an undifferentiated, proliferative state or terminally differentiates (Figure 4A). Because NMD and the miRNAs that operate in this circuit are mutually repressive (Figure 4F), this circuit “locks in” either the undifferentiated or differentiated cell state, depending on the input signal (see Discussion).

Conservation of the NMD-miRNA Regulatory Circuit

We examined whether the UPF1/miR-128 regulatory circuit is conserved in *X. laevis*. In support of this notion, the components of the circuit are conserved: (i) miR-128 is identical in sequence in *X. laevis* and mammals (Bruno et al., 2011), (ii) the miR-128 seed-sequence complementary binding region in the 3' UTR of *X. laevis upf1* and mammalian *UPF1* are identical (Bruno et al., 2011), and (iii) the UPF1 protein sequence is >90% identical in *Xenopus* and mammals (Figure S5A). In further support, we found that *upf1* mRNA level decreases during the development of the *X. laevis* presumptive neural tissue (the anterior ectoderm region) in a pattern inversely correlated with the induction of miR-128 (Bruno et al., 2011), just as *Upf1* mRNA levels do during mouse brain development (Figures S5B and S5C). This decrease in *upf1* mRNA levels coincides with an increase in all the direct NMD target transcripts that we examined—*atf3*, *axin2*, *dkk1*, *smad7*, and *cdkn1a*—during both *X. laevis* and mouse neural development (Figures S5B, S5C, and data not shown). Coupled with our previous finding that ectopic expression of miR-128 in *X. laevis* embryos downregulates NMD, as judged by assessing *X. laevis* NMD target transcripts (Bruno et al., 2011), these data strongly suggest that the UPF1/miR-128 circuit is conserved and regulated during anterior ectoderm embryonic development in *X. laevis*.

To assess whether the magnitude of NMD is depressed during *X. laevis* neural development, we turned to an *in vitro* system in which the mRNA encoding the neural inducer Noggin (a potent TGF- β /BMP inhibitor) is microinjected into the animal pole region of two-cell embryos to promote their differentiation into neural tissue when isolated at the late blastula stage and cultured *in vitro* (Lamb et al., 1993). We found that Noggin treatment dramatically reduced *Upf1* mRNA levels and increased the levels of direct NMD target transcripts *atf3*, *axin2*, *smad7* and *cdkn1a* (Figure 5A and data not shown), thereby recapitulating the molecular event occurring during the *in vivo* development of the anterior ectoderm region (Figures S5B and S5C) and providing evidence that the magnitude of NMD is repressed during *X. laevis* neural development. To examine the specificity of this response, we injected the mRNA encoding constitutively activated BMP receptor (CABR), which has the opposite effect: it promotes epidermal differentiation and represses neural differentiation (Suzuki et al., 1997). As expected, this treatment induced BMP-responsive genes and the epidermal differentiation marker *keratin*, but not neural markers (Figure 5B). Interestingly, *Upf1* mRNA expression was strongly upregulated by this epidermal differentiation protocol (Figure 5B), indicating that epidermal differentiation induces the opposite *upf1* response as compared to neural differentiation (Figure 5A). miR-128 expression was reduced under epidermal differentiation conditions (Figure S5D), providing further evidence for an opposite response. We conclude that the repression of NMD is a conserved and specific response that occurs during neural development.

To assess the functional relevance of this NMD downregulatory response, we manipulated Upf1 levels in *X. laevis* embryos. First, we inhibited Upf1 expression by injecting two-cell embryos with a morpholino (MO) complementary with the translation initiation region of *upf1* mRNA (Figure 5C). Consistent with the ability of MOs to only block translation, the Upf1 MO decreased Upf1 protein level, not *upf1* mRNA level (Figures 5D and S5E), which led to reduced NMD magnitude, based on the upregulation of 2 NMD target transcripts we tested: *axin2* and *smad7* (Figure 5D). The *upf1* MO also increased the expression of neural markers (Figure 5D), providing evidence that downregulation of Upf1 is sufficient to initiate the early stages of neural differentiation in *X. laevis*, just we showed it does in mammalian cells (Figure 1G and 1H). While *X. laevis* embryos treated with the *upf1* MO were viable in early stages, at the late gastrula stage they exhibited dose-dependent lethality (Table S4). Lethality at the gastrula stage was also elicited by modest overexpression of UPF1 (Table S4). Together, these results suggested that while the Upf1 downregulatory response promotes *X. laevis* neural differentiation, its expression must be fine-tuned to allow for the survival and development of early *X. laevis* embryos.

To investigate whether the UPF1 downregulatory response that occurs during *X. laevis* presumptive neural tissue development (Figure S5C) promotes neural differentiation just as it does in mammalian cells (Figures 1G and 1H), we elected to use a strategy that interferes with the ability of neurally induced miR-128 to downregulate UPF1. Thus, we designed 2 overlapping MOs that compete with miR-128 for binding to the *upf1* 3' UTR (Figure 5C). These *upf1* target protectors (TPs) blocked the ability of miR-128 to regulate an artificial miR-128 target substrate, *pLmiR-xU3m*, but not a mutant version with a debilitated miR-128-binding site (Figure 5E). We next examined whether the *upf1* TPs inhibited the downregulation of UPF1 that normally occurs during *X. laevis* development and found that, indeed, both TPs increased *upf1* mRNA and Upf1 protein levels in the anterior ectoderm region of stage-19 embryos (Figure 5F and data not shown).

The ability of the *upf1* TPs to prevent the downregulation of Upf1 that normally occurs during neural development allowed us to ask whether this Upf1 downregulatory response has the same role in neural maturation and proliferation in *X. laevis* embryonic development as it does in mammalian neural cells. We found that both *upf1* TPs reduced the expression of neural markers and both upregulated proliferation markers (Figure 5G), providing molecular evidence that the downregulation of UPF1 is required for terminating proliferation and inducing neuronal differentiation during neural development. To morphologically evaluate the effect of UPF1 modulation, we performed unilateral injections in 2 cells at the 4-cell embryo stage. As shown in Figure 6A, injection of the *upf1* TP elicited increased Upf1 protein expression in the side injected, as demonstrated by immunohistochemical analysis (particularly evident in the anterior region). Consistent with our finding that Upf1 promotes proliferation in mammalian cells (Figures 1I–L and S1H), we found that the side injected with the *upf1* TP exhibited tissue expansion (Figure 6A). This was likely the result of increased cellular proliferation, based on finding a considerably wider band of BrdU labeling on the *upf1* TP-injected side relative to the control side (Figure 6B). The *upf1* TP-injected side exhibited considerable cell proliferation in all epidermal regions, while the uninjected side only exhibited high proliferation in the anterior and neural fold edge areas. The *upf1* TP-injected side also exhibited repressed formation of neural tissues, including complete absence of lens and cement gland in the anterior region of embryos, as judged by whole-mount immuno-staining with the neural-marker Ncam (Figures 6C and D). As further evidence of repressed neural differentiation, immunofluorescence analysis showed that the particular regions of embryos that had increased Upf1 staining in response to *upf1* TP injection were the regions with decreased neural differentiation, as judged by Ncam staining (Figure 6E). Reduced Ncam staining was most prominent in the dorsal region of the neural tube (Figure 6E).

As a reciprocal test, we examined whether depressing UPF1 levels caused the converse effect: decreased cell proliferation and increased neural differentiation. Indeed, we found that the *upf1* MO triggered tissue shrinkage on the injected side (Figure 6F), consistent with decreased proliferation, and it increased Ncam staining, particularly in the regions with decreased Upf1 staining, such as the posterior region of the spinal cord (Figure 6G). The *upf1* MO also reduced the size of the spinal cord and disrupted the organization of the neural tissue, which normally form stacked, tightly patterned structures (Figure 6G). Taken together, these results indicated that Upf1 has a conserved role in promoting cellular proliferation and that its downregulation is required for *X. laevis* neural cells to exit the cell cycle and undergo differentiation.

DISCUSSION

The mechanisms underlying the decision whether an immature cell remains in an undifferentiated, proliferative cell state or commits to the post-mitotic differentiated cell state is an intriguing biological problem. In this paper, we provide evidence that this decision is controlled by an elaborate post-transcriptional circuit revolving around the NMD RNA degradation pathway (Figure 7). In particular, our results support the notion that the undifferentiated, stem-like cell state is stabilized by NMD's propensity to rapidly degrade mRNAs encoding pro-differentiation factors and proliferation inhibitors transcribed from genes not fully repressed by transcriptional mechanisms (Figures 2 and S2). In response to neural differentiation signals, NMD is downregulated (Figures 1A–C and S1A–C), which stabilizes these mRNAs, allowing for neural differentiation (Figures 2B and S2A). In support of this model, we found that preventing the downregulation of the key NMD factor, UPF1, inhibited neural differentiation and maintained the proliferative state (Figures 1D–F, K, and L). Furthermore, knockdown of UPF1 using RNAi was sufficient to trigger neural differentiation, promote neural maturation, and inhibit the proliferation of pluripotent cells (Figures 1G and 1H). Together, our results demonstrate that NMD is a crucial post-transcriptional mechanism controlling the switch between the pluripotent and differentiated cell states.

Our finding that NMD acts through the TGF- β signaling pathway to maintain the undifferentiated cell state (Figure 3) mechanistically connects the well-studied TGF- β signaling pathway with a post-transcriptional mechanism. Given the wealth of evidence that a blockade of TGF- β signaling is required for neural differentiation (Watabe and Miyazono, 2009), our discovery that NMD strongly promotes TGF- β signaling provides a mechanism by which NMD blocks neural differentiation. In particular, we found that the NMD downregulatory response triggered by neural differentiation cues cause stabilization of *Smad7* mRNA, which, in turn, leads to increased levels of SMAD7 protein, inhibited TGF- β signaling, and, consequently, the induction of neural differentiation (Figures 3 and S3A–B). To our knowledge, this is the first NMD circuit shown to control a specific biological outcome in higher eukaryotes. This is important since it has not been clear whether the ability of NMD to alter the levels of normal transcripts is physiologically significant. The many defects that have been described occurring in NMD-deficient organisms (Vicente-Crespo and Palacios, 2010) could, in principal, be entirely the result of toxicity emanating from the expression of abnormal proteins translated from aberrant PTC-containing mRNAs (e.g., generated by alternative splicing) that which would accumulate if NMD were not functioning (Chang et al., 2007; Nicholson et al., 2010)). Complementing our discovery of a NMD circuit that operates in mammals, it was recently shown that the ability of NMD to destabilize the mRNA encoding the copper transporter CTR2 is responsible for increasing the sensitivity of *Saccharomyces cerevisiae* to copper toxicity (Wang et al., 2011b).

Another non-mutually exclusive mechanism by which NMD may promote the undifferentiated cell state is by stimulating cell proliferation. Indeed our loss-of-function studies performed in both mouse cell lines and *X. laevis* embryos indicated that UPF1 is required for normal cell growth (Figures 1I–L, S1H, 6A, 6B, 6D, and 6F). This is consistent with previous loss-of-function studies that obtained evidence that NMD promotes cell proliferation (Avery et al., 2011; Weischenfeldt et al., 2008). Interestingly, studies have differed as to the phase of the cell cycle that they assign as being targeted by NMD. *D. melanogaster* cell lines depleted of various NMD factors were shown to be arrested at the G2/M phase of the cell cycle (Rehwinkel et al., 2005), depletion of UPF1 was found to inhibit the growth of HeLa cells at S phase (Azzalin and Lingner, 2006), and we found that depletion of UPF1 in P19 cells inhibited G1/S progression (Figures 1L and S1H). While the data from these loss-of-function studies support the notion that NMD promotes proliferation, an alternative possibility is that loss of NMD causes general toxicity, leading to depressed proliferation merely as a downstream consequence. We obtained two lines of evidence supporting a role for UPF1 in proliferation, rather than merely being required for cell survival. First, our gain-of-function studies showed that modest overexpression of UPF1 increased cellular proliferation in both mouse P19 cells and *X. laevis* embryos (Figures 1J–L, S1H, 6A, and 6B). Second, we showed that NMD selectively decreases the levels of mRNAs encoding proliferation inhibitor proteins, many of which we obtained evidence are direct NMD targets (Figures 2 and S2). This suggested that NMD not only promotes proliferation but it does so by acting directly on proliferation regulators.

We demonstrated that depletion of the NMD factor UPF1 was sufficient to both inhibit proliferation and trigger cellular neural differentiation in both mouse cells *in vitro* and *X. laevis* embryos *in vivo* (Figures 1G–I, 1L, 5D, 6F, 6G, and S1H). This suggests that the UPF1 downregulatory response that normally occurs during neural development is a critical rate-limiting step for neural differentiation (Figures 1A and S1A). Recently, another case in which withdrawal of a single factor triggers neural differentiation was reported: knockdown of the RNA-binding protein, PTB, was shown to reprogram differentiated non-neuronal cells into neurons (Xue et al., 2013). Interestingly, we identified other NMD factors—in addition to UPF1—that are downregulated during neural maturation (Figure 1A), raising the possibility that their downregulation may also contribute to neural development. However, we do not know whether these other factors are rate limiting for NMD in neural stem or progenitor cells. Indeed, a previous study showed that most NMD factors are *not* rate limiting for NMD in HeLa cells (Huang et al., 2011). Another consideration is that NMD is a branched pathway, each branch of which degrades different sets of mRNA substrates. Two of the NMD factors that we found were downregulated during neural maturation—UPF2 and UPF3B (Figure 1A)—are required for specific branches of the NMD pathway (Gehring et al., 2005; Chan et al., 2007; Huang et al., 2011). Thus the downregulation of these two NMD factors during neural maturation would be predicted to lead to stabilization of only a specific subset of NMD target mRNAs (assuming that UPF2 and UPF3B are rate limiting for NMD in neural precursor cells). Finally, we note that some NMD factors may have complex roles in which they promote some developmental steps and inhibit others. As a case in point, depletion of UPF3B was recently shown to inhibit the differentiation of neural progenitor cells (Jolly et al., 2013), while we obtained evidence that loss of UPF3B promotes the early differentiation of neural stem cells (Figure S1G). In the future, it will be important to determine whether modulation of specific NMD factors has clinical applications. Given that mutations in *UPF3B*—a gene essential for a branch of NMD—cause intellectual disability and are strongly associated with schizophrenia and autism in humans (Tarpey et al., 2007), this raises the possibility that modulation of the UPF3B-dependent branch of NMD could benefit patients with brain disorders.

We demonstrated that UPF1 functions in a conserved circuit with the miRNA, miR-128, in determining whether a cell proliferates or differentiates (Figures 4–6). A unique layer of regulation that we uncovered within this miR-128/UPF1 circuit is a negative feedback loop that we suggest stabilizes the output of the circuit. We found that UPF1 strongly represses miR-128 expression (Figures 4B and 4G), which coupled with the ability of miR-128 to repress UPF1 expression, creates mutually reinforcing negative feedback loops that would be predicted to form a bistable circuit (Figures 4A and F). In an undifferentiated cell, NMD is high, leading to suppressed miR-128 expression, which in turn perpetuates a high magnitude of NMD, thereby maintaining a stable undifferentiated cell state. In response to a neural differentiation signal that represses NMD, miR-128 is induced, which in turn further decreases the magnitude of NMD and reinforces miR-128 expression, thereby stabilizing the differentiated cell state. This circuitry also allows versatility since a neural differentiation signal whose primary action is to induce miR-128 rather than downregulate NMD (e.g., through repressed TGF- β signaling [Figure 4A]) would lead to the same outcome. We propose that this circuitry is reinforced by two other neurally expressed miRNAs: miR-9 and -124. We obtained evidence that, like miR-128, these two miRNAs repress the expression of NMD factors and are induced in response to repressed NMD (Figures 4C–E and G). In addition, both these miRNAs are primarily expressed in the nervous system and there is evidence that both regulate several events in neurons (Sun et al., 2013; Krichevsky et al., 2006). Another miRNA that may contribute to this regulation is miR-125, a neurally expressed miRNA that was recently shown to repress the expression of the NMD factor SMG1 (Wang et al., 2013) and promote the early neural specification of human embryonic stem cells (Boissart et al., 2012). Thus, there is growing constellation of miRNAs that are candidates to collaborate with miR-128 to repress NMD in neural precursor cells and thereby drive their differentiation.

In conclusion, our results support a model in which a conserved post-transcriptional circuit comprised of neural differentiation-inducing miRNAs, the TGF- β signaling pathway, and an RNA decay mechanism with selectivity for specific mRNAs, serves to help dictate the balance between stemness and differentiation. In the absence of any input, this circuit locks in the undifferentiated, proliferative cellular state. In response to neural differentiation signals, this circuit switches to a differentiation mode by stabilizing mRNAs that promote the non-proliferative, differentiated cell state. It will be of future interest to identify the nature of the input signals that switch this circuit between its two modes and whether approaches can be developed to modulate this circuit for the purposes of regenerative medicine.

EXPERIMENTAL PROCEDURES

Mammalian Cell Culture and Transfection

P19 cells were transiently transfected using Lipofectamine 2000 (Invitrogen). Unless otherwise noted, they were differentiated 8 hrs after transfection by culturing in the presence of RA (5×10^{-7} M) for 3 days. Primary mNSCs were isolated from E14 mouse brains and grown as neurospheres. They were differentiated by withdrawing the hormones, as described (Bruno et al., 2011; Yuan et al., 2011).

RNA, Luciferase, Protein Analysis, and Vectors

Total cellular RNA was isolated as described (Chan et al., 2007). qPCR analysis was done in triplicate as described (Chan et al., 2007). TaqMan-qPCR was performed using the TaqMan microRNA assay (Applied Biosystems). NMD activity was measured using the NMD reporter plasmids, pCI-NEO-WT PTC (–) and pCI-NEO-NS39 PTC (+), which both express Renilla luciferase (Boelz et al). They were cotransfected with pCI-NEO-FLY, a Firefly

luciferase control plasmid, two times within a 24 h interval in P19 cells. To measure NMD activity using the tetracycline (tet) promoter-based NMD reporters β -PTC (+) or β -PTC (-) (Singh et al., 2008), these plasmids were co-transfected into P19 cells with pTet.tTAK, which expresses the TRE activator tTA. The cells were incubated with doxycycline (which blocks tTA activity) for the times shown 3 days after treatment with RA or the diluent (EtOH) alone. The cells were treated with RA (5×10^{-7} M) 8 hrs after the second transfection. To determine RNA half-life of endogenous mRNAs, P19 cells were treated with Actinomycin D (5 μ g/ml) 48 hours after transfection. To determine the effect of cloned mRNA sequences on RNA stability, we used a tetracycline promoter-based NMD reporter system previously described in Yamashita and Ohno, 2010 (Yamashita and Ohno, 2010). Western blot analysis was performed as described (Chan et al., 2007). Immunofluorescence analysis of P19 cells was performed following the Cell Signaling Technologies protocol. Microscopic analysis and quantification of co-localized protein intensity was calculated using the Leica Acquisition Software (LAS) Colocalization AF6000. Vectors are described in the Extended Experimental Procedures. All primers sequences are provided in Table S5.

Identification of NMD-inducing Features

The following criteria were used to identify transcript with NMD-inducing features from the Ensemble database: (i) uORF defined by a ATG start site that encodes at least 10 amino acids; (ii) a 3' UTR at least 0.7 kb in length (based on the finding that >0.5 kb 3'UTR can trigger NMD [Singh et al. 2008]); (iii) an intron >55 nt from the 5' end of the 3'UTR. We only considered transcripts defined as full length in the database; e.g., those with an initiator ATG, valid stop codon, no frameshifts within the main reading frame, and consensus splice sites.

Cell-Cycle and Cell Count Analyses

For cell count analysis, cell counts were made with Trypan Blue using a hemocytometer. For cell-cycle analysis, cells were stained with propidium iodide and analyzed by flow cytometry.

X. laevis Procedures

The preparation of *X. laevis* embryos, their microinjection, and their culture was performed as described (Uzgare et al., 1998). Whole embryo injections were performed at the two-cell stage. Unilateral injections were performed in 2 cells at the 4-cell stage. BrdU labeling was performed following the Abcam BrdU labeling kit protocol (Abcam). Whole-mount staining was performed as described (Becker and Gard, 2006).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We are grateful to Amy Sater (University of Houston) and Christopher Kinter (Salk Institute) for providing *X. laevis* embryos and expression vectors. We also thank Xiaoyan Liao (UCSD) for bioinformatic support and Jens Lykke-Anderson (UCSD) for providing NMD factor expression vectors and antiserum. Finally, we thank Wilkinson laboratory members, Madhuvanthi Ramaiah, Hye-won Song, and Mimi H. Phan (UCSD), for their valuable experimental assistance and intellectual contributions. This work was supported by the NIH grant GM-58595 and CIRM grant RB4-06345.

References

- Avery P, Vicente-Crespo M, Francis D, Nashchekina O, Alonso CR, Palacios IM. Drosophila Upf1 and Upf2 loss of function inhibits cell growth and causes animal death in a Upf3-independent manner. *RNA*. 2011; 17:624–638. [PubMed: 21317294]
- Azzalin CM, Lingner J. The human RNA surveillance factor UPF1 is required for S phase progression and genome stability. *Curr Biol*. 2006; 16:433–439. [PubMed: 16488880]
- Bak M, Silahtaroglu A, Moller M, Christensen M, Rath MF, Skryabin B, Tommerup N, Kauppinen S. MicroRNA expression in the adult mouse central nervous system. *RNA*. 2008; 14:432–444. [PubMed: 18230762]
- Becker BE, Gard DL. Visualization of the cytoskeleton in *Xenopus* oocytes and eggs by confocal immunofluorescence microscopy. *Methods Mol Biol*. 2006; 322:69–86. [PubMed: 16739717]
- Boelz S, Neu-Yilik G, Gehring NH, Hentze MW, Kulozik AE. A chemiluminescence-based reporter system to monitor nonsense-mediated mRNA decay. *Biochem Biophys Res Commun*. 2006; 349:186–191. [PubMed: 16934750]
- Briones-Orta MA, Tecalco-Cruz AC, Sosa-Garrocho M, Caligaris C, Macias-Silva M. Inhibitory Smad7: emerging roles in health and disease. *Curr Mol Pharmacol*. 2011; 4:141–153. [PubMed: 21222648]
- Bruno IG, Karam R, Huang L, Bhardwaj A, Lou CH, Shum EY, Song HW, Corbett MA, Gifford WD, Gecz J, et al. Identification of a microRNA that activates gene expression by repressing nonsense-mediated RNA decay. *Mol Cell*. 2011; 42:500–510. [PubMed: 21596314]
- Chan WK, Huang L, Gudikote JP, Chang YF, Imam JS, MacLean JA 2nd, Wilkinson MF. An alternative branch of the nonsense-mediated decay pathway. *Embo J*. 2007; 26:1820–1830. [PubMed: 17363904]
- Chang YF, Imam JS, Wilkinson MF. The nonsense-mediated decay RNA surveillance pathway. *Annu Rev Biochem*. 2007; 76:51–74. [PubMed: 17352659]
- Dostie J, Dreyfuss G. Translation is required to remove Y14 from mRNAs in the cytoplasm. *Curr Biol*. 2002; 12:1060–1067. [PubMed: 12121612]
- Gehring NH, Kunz JB, Neu-Yilik G, Breit S, Viegas MH, Hentze MW, Kulozik AE. Exon-junction complex components specify distinct routes of nonsense-mediated mRNA decay with differential cofactor requirements. *Mol Cell*. 2005 Oct; Jul; 20(1):65–75. [PubMed: 16209946]
- Gong C, Kim YK, Woeller CF, Tang Y, Maquat LE. SMD and NMD are competitive pathways that contribute to myogenesis: effects on PAX3 and myogenin mRNAs. *Genes Dev*. 2009; 23:54–66. [PubMed: 19095803]
- Halder SK, Beauchamp RD, Datta PK. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. *Neoplasia*. 2005; 7:509–521. [PubMed: 15967103]
- Huang L, Lou CH, Chan W, Shum EY, Shao A, Stone E, Karam R, Song HW, Wilkinson MF. RNA homeostasis governed by cell type-specific and branched feedback loops acting on NMD. *Mol Cell*. 2012; 43:950–961. [PubMed: 21925383]
- Huang L, Wilkinson MF. Regulation of nonsense-mediated mRNA decay. *Wiley Interdiscip Rev RNA*. 2012; 3:807–828. [PubMed: 23027648]
- Jolly LA, Homan CC, Jacob R, Barry S, Gecz J. The UPF3B gene, implicated in intellectual disability, autism, ADHD and childhood onset schizophrenia regulates neural progenitor cell behaviour and neuronal outgrowth. *Hum Mol Genet*. 2013; 22:4673–4687. [PubMed: 23821644]
- Karam R, Wengrod J, Gardner LB, Wilkinson MF. Regulation of nonsense-mediated mRNA decay: Implications for physiology and disease. *Biochim Biophys Acta*. 2012
- Kim KM, Cho H, Kim YK. The upstream open reading frame of cyclin-dependent kinase inhibitor 1A mRNA negatively regulates translation of the downstream main open reading frame. *Biochem Biophys Res Commun*. 2012; 424:469–475. [PubMed: 22771799]
- Lamb TM, Knecht AK, Smith WC, Stachel SE, Economides AN, Stahl N, Yancopoulos GD, Harland RM. Neural induction by the secreted polypeptide noggin. *Science*. 1993; 262:713–718. [PubMed: 8235591]

- Liu Z, Lin X, Cai Z, Zhang Z, Han C, Jia S, Meng A, Wang Q. Global identification of SMAD2 target genes reveals a role for multiple co-regulatory factors in zebrafish early gastrulas. *J Biol Chem*. 2011; 286:28520–28532. [PubMed: 21669877]
- Massague J, Xi Q. TGF-beta control of stem cell differentiation genes. *FEBS Lett*. 2012; 586:1953–1958. [PubMed: 22710171]
- Melton C, Belloch R. MicroRNA Regulation of Embryonic Stem Cell Self-Renewal and Differentiation. *Adv Exp Med Biol*. 2010; 695:105–117. [PubMed: 21222202]
- Nakaya K, Murakami M, Funaba M. Regulatory expression of Brachyury and Goosecoid in P19 embryonal carcinoma cells. *J Cell Biochem*. 2008; 105:801–813. [PubMed: 18729134]
- Nicholson P, Joncourt R, Muhlemann O. Analysis of nonsense-mediated mRNA decay in mammalian cells. *Curr Protoc Cell Biol*. 2012; Chapter 27(Unit 27):24.
- Orford KW, Scadden DT. Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. *Nat Rev Genet*. 2008; 9:115–128. [PubMed: 18202695]
- Ozair MZ, Noggle S, Warmflash A, Krzyspiak JE, Brivanlou AH. SMAD7 directly converts human embryonic stem cells to telencephalic fate by a default mechanism. *Stem Cells*. 2013; 31:35–47. [PubMed: 23034881]
- Popp MW, Maquat LE. Organizing principles of Mammalian nonsense-mediated mRNA decay. *Annu Rev Genet*. 2013 Nov 23.47:139–65.10.1146/annurev-genet-111212-133424 [PubMed: 24274751]
- Rehwinkel J, Letunic I, Raes J, Bork P, Izaurralde E. Nonsense-mediated mRNA decay factors act in concert to regulate common mRNA targets. *RNA*. 2005; 11:1530–1544. [PubMed: 16199763]
- Schweingruber C, Rufener SC, Zund D, Yamashita A, Muhlemann O. Nonsense-mediated mRNA decay - Mechanisms of substrate mRNA recognition and degradation in mammalian cells. *Biochim Biophys Acta*. 2013
- Seuntjens E, Umans L, Zwijsen A, Sampaolesi M, Verfaillie CM, Huylebroeck D. Transforming Growth Factor type beta and Smad family signaling in stem cell function. *Cytokine Growth Factor Rev*. 2009; 20:449–458. [PubMed: 19892581]
- Singh G, Rebbapragada I, Lykke-Andersen J. A competition between stimulators and antagonists of Upf complex recruitment governs human nonsense-mediated mRNA decay. *PLoS Biol*. 2008; 6:e111. [PubMed: 18447585]
- Smirnova L, Grafe A, Seiler A, Schumacher S, Nitsch R, Wulczyn FG. Regulation of miRNA expression during neural cell specification. *Eur J Neurosci*. 2005; 21:1469–1477. [PubMed: 15845075]
- Sun AX, Crabtree GR, Yoo AS. MicroRNAs: regulators of neuronal fate. *Curr Opin Cell Biol*. 2013; 25:215–221. [PubMed: 23374323]
- Suzuki A, Kaneko E, Ueno N, Hemmati-Brivanlou A. Regulation of epidermal induction by BMP2 and BMP7 signaling. *Dev Biol*. 1997; 189:112–122. [PubMed: 9281341]
- Tani H, Torimura M, Akimitsu N. The RNA degradation pathway regulates the function of GAS5 a non-coding RNA in mammalian cells. *PLoS One*. 2013; 8:e55684. [PubMed: 23383264]
- Tarpey PS, Raymond FL, Nguyen LS, Rodriguez J, Hackett A, Vandeleur L, Smith R, Shoubridge C, Edkins S, Stevens C, et al. Mutations in UPF3B, a member of the nonsense-mediated mRNA decay complex, cause syndromic and nonsyndromic mental retardation. *Nat Genet*. 2007; 39:1127–1133. [PubMed: 17704778]
- Uzgare AR, Uzman JA, El-Hodiri HM, Sater AK. Mitogen-activated protein kinase and neural specification in *Xenopus*. *Proc Natl Acad Sci U S A*. 1998; 95:14833–14838. [PubMed: 9843975]
- van der Heyden MA, Defize LH. Twenty one years of P19 cells: what an embryonal carcinoma cell line taught us about cardiomyocyte differentiation. *Cardiovasc Res*. 2003; 58:292–302. [PubMed: 12757864]
- Vicente-Crespo M, Palacios IM. Nonsense-mediated mRNA decay and development: shoot the messenger to survive? *Biochem Soc Trans*. 2010; 38:1500–1505. [PubMed: 21118115]
- Wang D, Zavadil J, Martin L, Parisi F, Friedman E, Levy D, Harding H, Ron D, Gardner LB. Inhibition of nonsense-mediated RNA decay by the tumor microenvironment promotes tumorigenesis. *Mol Cell Biol*. 2011a; 31:3670–3680. [PubMed: 21730287]

- Wang X, Okonkwo O, Kebaara BW. Physiological basis of copper tolerance of *Saccharomyces cerevisiae* nonsense-mediated mRNA decay mutants. *Yeast*. 2011b; 30:179–190. [PubMed: 23450501]
- Wang G, Jiang B, Jia C, Chai B, Liang A. MicroRNA 125 represses nonsense-mediated mRNA decay by regulating SMG1 expression. *Biochem Biophys Res Commun*. 2013; 435:16–20. [PubMed: 23583196]
- Watabe T, Miyazono K. Roles of TGF-beta family signaling in stem cell renewal and differentiation. *Cell Res*. 2009; 19:103–115. [PubMed: 19114993]
- Weischenfeldt J, Damgaard I, Bryder D, Theilgaard-Monch K, Thoren LA, Nielsen FC, Jacobsen SE, Nerlov C, Porse BT. NMD is essential for hematopoietic stem and progenitor cells and for eliminating by-products of programmed DNA rearrangements. *Genes Dev*. 2008; 22:1381–1396. [PubMed: 18483223]
- Xue K, Ng JH, Ng HH. Mapping the networks for pluripotency. *Philos Trans R Soc Lond B Biol Sci*. 2011; 366:2238–2246. [PubMed: 21727129]
- Yepiskoposyan H, Aeschmann F, Nilsson D, Okoniewski M, Muhlemann O. Autoregulation of the nonsense-mediated mRNA decay pathway in human cells. *RNA*. 2011; 17:2108–2118. [PubMed: 22028362]
- Yamashita A, Ohno S. Analysis of nonsense-mediated mRNA decay by monitoring mRNA half-lives in mammalian cells. *Cold Spring Harb Protoc*. 2010 pdb prot5386.
- Yuan SH, Martin J, Elia J, Flippin J, Paramban RI, Hefferan MP, Vidal JG, Mu Y, Killian RL, Israel MA, et al. Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. *PLoS One*. 2011; 6:e17540. [PubMed: 21407814]

Highlights

- The NMD/RNA decay factor, UPF1, promotes the undifferentiated cell state
- UPF1 acts in a conserved circuit with specific miRNAs and TGF β signaling components
- Neural differentiation is promoted by UPF1 downregulation
- Negative feedback loops stabilize the stem-like and differentiated cell states




Figure 1. UPF1 is Downregulated to Permit Neural Differentiation

(A) Quantitative polymerase chain reaction (qPCR) analysis of NMD factor transcript levels in mNSCs incubated in differentiation media for the times indicated.

(B and C) NMD activity is decreased during neural differentiation. P19 cells treated with RA to induce differentiation were analyzed for NMD activity using the NMD reporters developed by Boelz *et al.* (2006) (B) and Singh *et al.* (2008) (C), as described in the Extended Experimental Procedures.

(D–F) Rescue of UPF1 expression suppresses neural differentiation. qPCR (D), Western (E), and Immunofluorescence (F) analyses of P19 cells transfected with the UPF1 expression vector (Ev-Upf1) or empty vector (Ev-C) and treated with RA. mRNA levels (D) are relative to P19 cells not incubated with RA, which were given a value of 1. Western analysis quantification (E) is the mean of three experiments, normalized against β -ACTIN; error bars represent standard deviation (SD). Immunofluorescence analysis (F) is of UPF1 (red),

NESTIN (green), and DAPI (blue); the box plot shows the distribution of protein levels in individual cells (see Extended Experimental Procedures for details).

(G, H) Suppression of Upf1 expression is sufficient to induce neural differentiation and promote neural maturation. qPCR analysis of P19 cells (G) and mNSCs (H) transfected with either UPF1 siRNA or Luciferase (Luc) siRNA (the latter is the negative control, which was given a value of 1). The P19 cells were cultured in the absence of RA.

(I–L) The Upf1 downregulatory response is necessary and sufficient to inhibit cellular proliferation. Cell-counting experiments performed in P19 cells treated and transfected as indicated (I–K; n=6). Cell-cycle analysis of P19 cells treated and transfected as indicated (L; n=3). Error bars represent SD.

Statistical analysis for all figure panels was done using the paired Student's t test (asterisks denote statistically significant differences; $p < 0.05$). Unless otherwise noted, all experiments were repeated 3 times and error bars depict standard error mean (SEM). Transcript levels were normalized to the level of L19 RNA for all qPCR experiments.





Figure 2. UPF1 Promotes the Decay of mRNAs Encoding Proliferation Inhibitors and Differentiation Factors

(A) qPCR analysis of transcripts encoding the indicated classes of proteins in Upf1-depleted (siUpf1) P19 cells. The fold change of mRNA level is relative to that in control cells treated with a siRNA against luciferase (siLuc). mRNA normalization and statistical analysis were performed as in Figure 1.

(B) RNA decay of selected mRNAs in P19 cells transfected as indicated (see Figure S2 for analysis of more mRNAs). Transcripts levels were normalized to the level of *Gapdh* mRNA, which is relatively stable.



(J) UPF1 promotes mesodermal differentiation by targeting *Smad7* mRNA. qPCR analysis of *Brachyury (T)* and *Goosecoid (Gsc)* mRNA in P19 cells incubated and transfected the agents indicated. mRNA levels are relative to cells transfected with siLuc/shRNA-C, which were given a value of 1.

Quantification and statistical analysis for all data panels was done as in Figure 1, unless otherwise noted.




Figure 4. A Post-transcriptional Circuit that Influences Differentiation vs. Proliferation Decisions

(A) Model: miR-128 and UPF1 oppose each other in a circuit that controls neural differentiation and proliferation.

(B) Taqman-qPCR analysis of miR-128 levels in P19 cells, normalized against U6 snRNA. miR-128 levels are relative to cells treated the negative control, EtOH/siLuc, which had a background PCR signal (N.D.) that was assigned a value of “1” to provide a conservative estimate of miR-128 induction in response to the other treatments.

(C) Conservation of putative miRNA targets sites in the *Upf3b* 3' UTR. *Has*, *Homo sapiens*; *Mmu*, *Mus musculus*; *Ptr*, *Pan troglodytes*; *Mml*, *Macaca mulatta*; *Ocu*, *Oryctolagus cuniculus*; *Gga*, *Gallus gallus*; *Xtr*, *Xenopus tropicalis*.

(D) Luciferase expression from the pMiR-Luc-3B reporter harboring the full-length *Upf3b* 3' UTR cotransfected into HeLa cells with the indicated miRNA mimic or the negative-control mimic (miR-C).

(E) Left: qPCR analysis of HeLa cells transfected as indicated. Middle and right: Western blot analysis of P19 cells with a miR-9 inhibitor (miR-9 inh) or negative control inhibitor (miR-C Inh), quantified as in Figure 1E.

(F) Model: NMD and neurally expressed miRNAs mutually suppress each other, which serves to lock in a given cell state.

(G) Repression of NMD induces NMD-inhibitory miRNAs. Taqman-qPCR analysis of mNSCs (wild type (WT) on the left; WT and *Upf3b*-null on the right) transfected with the indicated siRNAs and miRNA mimics.

Quantification and statistical analysis of all data panels was done as in Figure 1, unless otherwise noted.




Figure 5. Conservation of the UPF1-miR-128 Regulatory Circuit

(A, B) qPCR analysis of isolated *X. laevis* ectoderm tissue derived from embryos injected with *noggin* (*nog*) and *constitutive activated bmp receptor* (*cabr*) mRNA to induce neural and epidermal differentiation. β -galactosidase mRNA serves as the injection control. *smad7* and *axin2* are NMD target transcripts. Keratin is an epidermal (Epi) marker. The *muscle* (*m-actin*) mesoderm marker is not detectable (N.D.), indicating no mesodermal tissue contamination.

(C–G) Evidence that miR-128 drives *X. laevis* neural differentiation by repressing UPF1 levels. (C) Diagram depicting the target protector (TP) morpholinos (MO) that prevent miR-128 binding to the UPF1 3' UTR and the *upf1* MO that blocks UPF1 translation. (D) qPCR analysis of isolated ectodermal tissue derived from embryos injected with the MOs indicated. (E) Luciferase analysis of embryos injected with the indicated molecules and cultured until stage (st) 12 (TP-C is a negative control TP MO). (F) Western blot analysis of isolated *X. laevis* ectoderm tissues derived from embryos injected with the indicated morpholinos (5 embryos per samples, normalized against β -Actin). (G) qPCR analysis of isolated *X. laevis* ectoderm tissues treated as in panel F.

(H) Model: conservation of the UPF1-miR-128 regulatory circuit.
Quantification and statistical analysis of all data panels was performed as in Figure 1.




Figure 6. The UPF1/miR-128 Circuit Controls *X. laevis* Cell Proliferation and Differentiation
 (A, B) miR-128 inhibits *X. laevis* cellular proliferation by repressing UPF1. (A) St 33 embryos stained for UPF1 expression (brown) unilaterally injected with a MO blocking miR-128 binding to the *upf1* 3' UTR (TP-1 [see Figure 5C]). The TP-1 injected side had elevated UPF1 levels and more extensive tissue expansion (white arrow-head) than the non-injected side (similar results were obtained with TP-II [data not shown]). (B) BrdU labeling of embryos unilaterally injected as in panel A (red denotes BrdU-labeled cells). Increased cell proliferation was observed on the TP-II injected side.
 (C–E) miR-128 promotes *X. laevis* neural differentiation by repressing UPF1. (C) Diagram of embryo injected with *upf1* TPs. (D) St 33 (left) and st 25 (right) embryos unilaterally injected and stained for Ncam (Red) and Upf1 (Brown) expression. The side injected with *upf1* TPs had greater Upf1 expression/tissue growth (yellow asterisks) and lower Ncam expression (yellow arrow-heads) than the non-injected side. (E) Dorsal-ventral cross-section of a st 25 embryo unilaterally injected and stained for Upf1 (green) and Ncam (red) expression.
 (F, G) Upf1 promotes neural proliferation. (F) St 25 (left) and st 28 (right) embryos unilaterally injected at the 4-cell stage with the *upf1* MO (Figure 5C) and stained for Upf1 expression (brown). The *upf1* MO-injected side had lower UPF1 expression (white arrow-heads) and failed to expand (red asterisks) as much as the non-injected side. (G) Anterior-posterior cross section of a st 28 embryo unilaterally injected and stained for Upf1 (green)

and Ncam (red) expression. The *upfl* MO-injected side had lower Upfl expression, higher Ncam expression, and disorganized neural tissue (white arrow-head).

An, anterior; b, brain; c.g., cement gland; n.f., neural fold; n.t., neural tube; o.c., optical cup; po: posterior; s.c., spinal cord.




Figure 7.
 Model: A Post-Transcriptional Switch that Controls Neural Stem Cell Fate